Intelligence · Clinical Development
Pipeline search results
Programs matching “non-small-cell-lung-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 211 pipeline programs matching "non-small-cell-lung-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
PLD and Carboplatin
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
PM8002
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Non-Small Cell Lung Cancer
1 trial -
Pegylated Irinotecan
Nektar Therapeutics UK Limited
Stage IV Non-small Cell Lung Cancer (NSCLC)
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Advanced Non-Small Cell Lung Cancer
1 trial -
Pembrolizumab 200 mg
Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer
1 trial -
Pembrolizumab 200 mg IV infusion
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stage IIIB(N2) Non-small Cell Lung Cancer
1 trial -
Pembrolizumab/Vibostolimab coformulation
Merck KGaA, Darmstadt, Germany
Metastatic Non Small Cell Lung Cancer
1 trial -
Pemetrexed and Reolysin (and safety run-in)
ONCOLYTICS BIOTECH INC
Non Small Cell Lung Cancer
1 trial -
Pre-operative chemotherapy
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Pulmonary Rehabilitation (PR)
United Therapeutics Europe Ltd
Non-small Cell Lung Cancer Stage III
1 trial -
RMC-4630
Revolution Medicines
Non-Small Cell Lung Cancer
1 trial -
RMC-6236
Revolution Medicines
Non-small Cell Lung Cancer (NSCLC)
1 trial -
Recombinant human endostatin
The First People's Hospital of Lianyungang
Stage III Non-small-Cell Lung Cancer
1 trial -
S-1
United Therapeutics Europe Ltd
Advanced Non-Small Cell Lung Cancer
2 trials -
S095018
Regeneron UK Limited
Non-small Cell Lung Cancer (NSCLC)
1 trial -
SHR-1701 Combined With Fluazopalil
Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer
1 trial -
SI-B001
Sichuan Baili Pharmaceutical Co.,
Non Small Cell Lung Cancer
1 trial -
Sacituzumab Tirumotecan and Limertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
EGFR-mutant Non-small Cell Lung Cancer
1 trial -
Savolitinib
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Non-small Cell Lung Cancer
1 trial -
Sindillimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer Stage III
1 trial -
Sintilimab Combined with Platinum-containing Chemotherapy
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.